Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...
The dopamine hypothesis of schizophrenia is a scientific theory that suggests dopamine directly contributes to schizophrenia symptoms. Research on this theory and other causes of schizophrenia is ...
Maybe you’d like to spend time on hobbies or hang out with friends, but nothing feels as exciting and engaging as it used to –– so you just squander another hour on social media. Your problem may have ...
Clinical Trials Arena on MSN
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results